SG Americas Securities LLC bought a new position in Krystal Biotech Inc (NASDAQ:KRYS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 20,676 shares of the company’s stock, valued at approximately $856,000.
Several other institutional investors have also recently added to or reduced their stakes in the company. Exane Derivatives bought a new stake in Krystal Biotech in the first quarter worth approximately $87,000. Victory Capital Management Inc. raised its stake in shares of Krystal Biotech by 21.0% in the 4th quarter. Victory Capital Management Inc. now owns 2,104 shares of the company’s stock valued at $117,000 after buying an additional 365 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in shares of Krystal Biotech by 26.3% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,334 shares of the company’s stock worth $144,000 after purchasing an additional 695 shares during the last quarter. UBS Asset Management Americas Inc. bought a new stake in Krystal Biotech during the 4th quarter worth about $227,000. Finally, IndexIQ Advisors LLC bought a new stake in Krystal Biotech during the 1st quarter worth about $203,000. 66.18% of the stock is currently owned by institutional investors and hedge funds.
In other Krystal Biotech news, COO Suma Krishnan sold 50,000 shares of Krystal Biotech stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $43.50, for a total value of $2,175,000.00. Following the transaction, the chief operating officer now owns 1,928,486 shares in the company, valued at $83,889,141. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 27.40% of the company’s stock.
Krystal Biotech stock opened at $41.29 on Friday. Krystal Biotech Inc has a 12-month low of $31.89 and a 12-month high of $66.85. The company has a current ratio of 46.38, a quick ratio of 46.38 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $43.07 and its two-hundred day moving average price is $48.84.
Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.13. As a group, equities research analysts forecast that Krystal Biotech Inc will post -2.19 EPS for the current year.
KRYS has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a research report on Friday, May 8th. Chardan Capital reaffirmed a “buy” rating and set a $100.00 price target on shares of Krystal Biotech in a research note on Friday, May 8th. BidaskClub raised shares of Krystal Biotech from a “sell” rating to a “hold” rating in a research note on Wednesday, June 17th. William Blair reaffirmed a “buy” rating on shares of Krystal Biotech in a research report on Monday, May 4th. Finally, Evercore ISI started coverage on shares of Krystal Biotech in a research report on Thursday, June 4th. They set an “outperform” rating and a $90.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $76.67.
Krystal Biotech Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.
Read More: Understanding Price to Earnings Ratio (PE)
Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech Inc (NASDAQ:KRYS).
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.